Why Did Esperion Therapeutics Shares Soar 11.7%?

Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares surged 11.7% in pre-market trading on April 24, 2025, driven by a series of strategic announcements and developments.

Esperion Therapeutics, Inc. has announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before the market opens. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. This event is expected to offer insights into the company's performance and future strategies, potentially influencing investor sentiment and stock price movements.

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing innovative medicines for patients at risk for cardiovascular disease. The company's portfolio includes the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial, which has provided robust data on their efficacy and safety.

Esperion Therapeutics, Inc. continues to build on its success with its next generation program, which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi enable rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. This ongoing research and development effort is crucial for the company's long-term growth and competitiveness in the biopharmaceutical industry.